11.1 Central Disorders of Hypersomnolence

11.1 Central Disorders of Hypersomnolence

Quick Answer: Central disorders of hypersomnolence are neurological conditions defined by excessive daytime sleepiness (EDS) not caused by nocturnal sleep deprivation, sleep-disordered breathing, or circadian misalignment. Narcolepsy Type 1 (NT1) is driven by loss of most of the roughly 70,000 hypocretin/orexin-producing neurons in the lateral hypothalamus (thought to be autoimmune), strongly associated with HLA-DQB1*06:02 and marked by CSF hypocretin-1 $\le 110\text{ pg/mL}$ and cataplexy. Narcolepsy Type 2 (NT2) presents with objective sleepiness on the Multiple Sleep Latency Test (MSLT; Mean Sleep Latency $\le 8.0\text{ min}$ with $\ge 2$ SOREMPs) but lacks cataplexy and hypocretin deficiency. Idiopathic Hypersomnia (IH) presents with severe unrefreshing sleep, severe "sleep drunkenness" (prolonged confusional awakenings), and either an MSLT mean sleep latency $\le 8$ minutes or 24-hour sleep of at least 660 minutes, with fewer than 2 SOREMPs.

Central disorders of hypersomnolence represent primary disorders of central sleep-wake regulation. For the Clinical Sleep Health Specialist (CCSH), mastering the neurochemical foundations, precise polysomnographic and MSLT testing criteria, and targeted pharmacotherapy is vital for differentiating primary central hypersomnias from secondary causes of daytime somnolence.

---

Narcolepsy Type 1 (NT1): Pathophysiology, Neurobiology & Genetics

Narcolepsy Type 1 (NT1) is an incurable, chronic neurological disorder of REM sleep gating and state boundary control. The underlying pathophysiology is selective loss, thought to be immune-mediated, of most of the roughly 70,000 hypocretin (orexin) neurons in the lateral and posterior hypothalamus.

The Role of Hypocretin / Orexin in Sleep Architecture

Hypocretin-1 (orexin-A) and hypocretin-2 (orexin-B) are excitatory neuropeptides synthesized in the perifornical and lateral hypothalamic areas. These peptides project diffusely to monoaminergic and cholinergic nuclei of the ascending reticular activating system (ARAS), including:

• Locus coeruleus (norepinephrine)
• Dorsal raphe nuclei (serotonin)
• Tuberomammillary nucleus (histamine)
• Ventral tegmental area / substantia nigra (dopamine)
• Basal forebrain and pedunculopontine/laterodorsal tegmental nuclei (acetylcholine)

In the flip-flop switch model of sleep-wake control, hypocretin acts as a critical stabilizer. It reinforces wakefulness by exciting monoaminergic arousal centers, which in turn inhibit the sleep-promoting GABAergic neurons of the ventrolateral preoptic nucleus (VLPO). When hypocretinergic signaling is abolished, the flip-flop switch becomes profoundly unstable, leading to rapid, unpredictable state transitions: wakefulness intrudes abruptly into sleep, and elements of REM sleep (such as skeletal muscle atonia, vivid dreaming, and saccadic eye movements) intrude directly into wakefulness.

Genetic Predisposition & Biomarkers

NT1 exhibits the strongest known human leukocyte antigen (HLA) association of any disease. More than $98\%$ of individuals with NT1 carry the specific major histocompatibility complex class II allele HLA-DQB1*06:02 (often paired with HLA-DQA101:02). While HLA-DQB106:02 is present in roughly $12\%$ to $38\%$ of the general population, depending on ancestry—meaning its presence is not independently diagnostic—its absence makes a diagnosis of NT1 exceedingly improbable ($>99\%$ negative predictive value).

Environmental triggers, including seasonal infections such as Streptococcus pyogenes pharyngitis and the H1N1 influenza pandemic/antigen exposure, are recognized triggers that induce cross-reactive molecular mimicry in genetically vulnerable individuals, triggering autoimmune T-cell-mediated destruction of hypocretin neurons.

Diagnostic Biomarker: Cerebrospinal Fluid (CSF) Hypocretin-1

Direct measurement of CSF hypocretin-1 through lumbar puncture provides the definitive biochemical biomarker for NT1:

• Deficiency Standard: CSF hypocretin-1 concentration $\le 110\text{ pg/mL}$ (or less than one-third of the standardized mean value in healthy control subjects).
• Under ICSD-3 criteria, a documented CSF hypocretin-1 level $\le 110\text{ pg/mL}$ establishes a diagnosis of Narcolepsy Type 1 even if an MSLT has not yet been performed or yields inconclusive results (e.g., in patients unable to tolerate withdrawal of REM-suppressing medications).

---

The Clinical Tetrad & Nocturnal Sleep Fragmentation

While the classic "narcoleptic tetrad" is historically celebrated, fewer than one-third of patients manifest all four classic features at symptom onset. Recognizing each component is essential for clinical navigation.

1. Excessive Daytime Sleepiness (EDS): Present in $100\%$ of patients and typically the earliest symptom. It is characterized by unavoidable, irresistible "sleep attacks" occurring during sedentary tasks (reading, meetings) and active situations (talking, eating, driving). Daytime naps are typically brief ($15\text{–}30\text{ minutes}$) and distinctly refreshing, though sleepiness recurs within 1 to 2 hours.
2. Cataplexy: Pathognomonic for NT1. Cataplexy is the sudden, brief, bilateral loss of skeletal muscle tone provoked by strong, typically positive emotions. Laughter, joking, and surprise are the most potent triggers; anger or anticipation may also trigger episodes. Consciousness, auditory perception, and memory are fully preserved throughout the event.
   • Mild / Partial Cataplexy: Drooping jaw (slack face), dysarthria, head drop, knee buckling, or hand weakness.
   • Severe / Complete Cataplexy: Generalized bilateral collapse to the floor with temporary paralysis lasting from several seconds to 2 minutes, rarely exceeding 3 minutes. Extraocular muscles and the diaphragm are spared.
3. Hypnagogic & Hypnopompic Hallucinations: Vivid, bizarre, often terrifying multi-sensory experiences occurring at sleep onset (hypnagogic) or upon awakening (hypnopompic). These represent dream imagery intruding into conscious awareness. Auditory and visual sensations predominate, frequently involving malevolent intruders or animals in the room.
4. Sleep Paralysis: A temporary inability to perform voluntary movements or vocalize during sleep-wake transitions, lasting from seconds to several minutes. Like cataplexy, it results from REM-associated spinal motor neuron hyperpolarization (glycinergic and GABAergic inhibition) persisting into wakefulness. Extraocular motion and respiration remain intact, but patients experience severe panic.
5. Nocturnal Sleep Fragmentation: Although patients fall asleep almost instantaneously, nocturnal sleep architecture is severely disrupted. Patients experience repetitive nocturnal awakenings, frequent stage shifts, and prominent motor restlessness, reflecting the inability of the hypocretin-deficient brain to sustain consolidated sleep states.

---

Narcolepsy Type 2 (NT2) & Idiopathic Hypersomnia (IH)

Narcolepsy Type 2 (NT2)

Narcolepsy Type 2 accounts for a substantial minority of narcolepsy diagnoses (estimates vary widely between studies). Patients present with severe, disabling excessive daytime sleepiness and positive MSLT findings (MSL $\le 8.0\text{ min}$ and $\ge 2$ SOREMPs) but exhibit:

• Absolute absence of cataplexy.
• Normal CSF hypocretin-1 levels ($>110\text{ pg/mL}$ or $>1/3$ control values), if measured.
• Less consistent HLA-DQB1*06:02 association ($~50\%$ of patients).

Idiopathic Hypersomnia (IH)

Idiopathic Hypersomnia is a distinct central disorder of hypersomnolence characterized by an unyielding need for sleep without the dissociated REM phenomena typical of narcolepsy.

• Diagnostic Criteria (ICSD-3):
  1. Daily irrepressible need to sleep or daytime lapses into sleep occurring for at least 3 months.
  2. Absence of cataplexy.
  3. Fewer than 2 SOREMPs on the MSLT, or none if the preceding PSG already showed a SOREMP.
  4. At least one of: an MSLT mean sleep latency $\le 8$ minutes, or a 24-hour total sleep time $\ge 660$ minutes (11 hours) on 24-hour PSG or on wrist actigraphy with a sleep log averaged over at least 7 days of unrestricted sleep.
  5. Insufficient sleep syndrome and other causes are excluded.

A long nocturnal sleep on the diagnostic PSG supports the diagnosis but is not itself a criterion.

• Clinical Hallmarks:
  • Severe Sleep Drunkenness (sleep inertia): Extreme, prolonged difficulty awakening from sleep accompanied by cognitive blunting, ataxia, confusion, irritability, and repeated return to sleep, lasting from 30 minutes to several hours.
  • Non-Restorative Sleep: Unlike narcolepsy, daytime naps in IH are typically prolonged ($>1\text{–}2\text{ hours}$), non-refreshing, and do not alleviate sleepiness.

---

Standard Diagnostic Testing Protocol: PSG Followed by MSLT

Accurate diagnosis of central hypersomnolence disorders requires rigorous adherence to standardized AASM protocols combining nocturnal polysomnography with the next-day Multiple Sleep Latency Test.

Pre-Test Preparation & Medication Washout

1. Sleep Satiety & Sleep Logs: Patients must complete a continuous sleep diary and wrist actigraphy for at least 7 to 14 days prior to testing to verify regular sleep schedules and confirm that total nocturnal sleep time exceeds 7 hours per night, eliminating chronic insufficient sleep syndrome as a confounder.
2. Drug Washout: Medications affecting sleep architecture must be discontinued well in advance:
   • REM-suppressing, alerting and sedating medications (SSRIs, SNRIs, TCAs, stimulants and wake-promoting agents) should ideally be stopped at least 2 weeks before the MSLT (or about 5 half-lives; up to 6 weeks for long-acting drugs such as fluoxetine), only under the prescriber's direction. Recent withdrawal can cause rebound SOREMPs, and continued use can mask them.
   • A urine drug screen (UDS) is collected on the morning of the MSLT to confirm the absence of sedatives, stimulants, illicit substances, or unprescribed psychoactive compounds.

Nocturnal Polysomnography (PSG)

• The patient undergoes diagnostic PSG immediately preceding the MSLT.
• Prerequisites for MSLT Validity: Total Sleep Time (TST) must be $\ge 6.0\text{ hours}$ (360 minutes). If the patient sleeps $<6$ hours, the MSLT must be postponed due to the risk of false-positive short sleep latencies from acute sleep restriction.
• Sleep-Onset REM Period (SOREMP) Scoring: A nocturnal SOREMP is scored if REM sleep occurs within 15 minutes of sleep onset on the diagnostic PSG. An unequivocal nocturnal PSG SOREMP is highly specific for narcolepsy and is permitted by AASM criteria to count as one of the two SOREMPs required for an NT1 or NT2 diagnosis.
• Nocturnal PSG confirms or excludes alternative causes of EDS, such as severe untreated obstructive sleep apnea (AHI $\ge 15$).

Multiple Sleep Latency Test (MSLT) Protocol

• Testing begins 1.5 to 3 hours after nocturnal awakening.
• Consists of 5 scheduled nap opportunities at 2-hour intervals; the AASM 2021 protocol allows stopping after 4 naps only when the result is already clearly diagnostic of narcolepsy.
• Each nap trial is conducted in a quiet, dark, temperature-controlled environment with standard 10-20 EEG, EOG, and chin EMG montage.
• Nap Trial Rules:
  • If no sleep occurs: The trial is terminated after 20 minutes, and sleep latency is recorded as 20 minutes.
  • If sleep occurs (defined as the first epoch of any sleep stage, typically N1): The nap continues for 15 minutes of clock time after the first epoch of sleep to detect REM sleep.
  • All five naps are completed unless the first four already show a clearly diagnostic result (mean latency ≤8 minutes with 2 or more SOREMPs, one of which may come from the preceding PSG).

$\text{Mean Sleep Latency (MSL)} = \frac{\sum \text{Sleep Latencies across all trials}}{\text{Total Number of Nap Trials}}$

---

Diagnostic Criteria Matrix: NT1, NT2, and Idiopathic Hypersomnia

Pharmacotherapy for Central Disorders of Hypersomnolence

Effective management requires a multimodal approach combining targeted pharmacotherapy with scheduled behavioral naps ($15\text{–}20\text{ minutes}$) and sleep hygiene optimization.

The AASM's 2021 treatment guideline strongly recommends modafinil, pitolisant, sodium oxybate and solriamfetol for narcolepsy and conditionally recommends armodafinil, dextroamphetamine and methylphenidate. For idiopathic hypersomnia it strongly recommends modafinil and conditionally recommends clarithromycin, methylphenidate, pitolisant and sodium oxybate. Low-sodium oxybate (Xywav) was FDA-approved for narcolepsy in 2020 and for idiopathic hypersomnia in 2021.

1. Wake-Promoting Agents (First-Line for EDS)

• Modafinil & Armodafinil: Atypical dopamine reuptake inhibitors that bind the dopamine transporter (DAT) with low affinity, increasing extracellular dopamine in cortical and hypothalamic pathways with minimal peripheral sympathomimetic activation.
  • Clinical Safety Alert: Both modafinil and armodafinil are potent inducers of the hepatic CYP3A4 enzyme system. They significantly enhance the metabolic clearance of estrogen- and progestin-containing hormonal contraceptives, rendering oral contraceptives, contraceptive implants, and transdermal patches unreliable. Clinical sleep specialists must educate female patients of childbearing potential to utilize alternative non-hormonal contraception (such as copper or levonorgestrel intrauterine devices [IUDs] or barrier methods) during therapy and for at least 1 month following discontinuation.
• Pitolisant (Wakix): A first-in-class selective histamine $H_3$ receptor antagonist / inverse agonist. By blocking presynaptic autoreceptors and heteroreceptors, pitolisant increases histamine release in the cerebral cortex and hypothalamus. It also promotes the release of acetylcholine, dopamine, and norepinephrine. Pitolisant improves both EDS and cataplexy in NT1 without abuse liability (non-scheduled agent). It carries a warning for QT prolongation, and it can also reduce the effectiveness of hormonal contraceptives, so its labeling advises an alternative non-hormonal method during treatment and for at least 21 days after stopping.
• Solriamfetol (Sunosi): A selective dopamine and norepinephrine reuptake inhibitor (DNRI) approved for EDS in narcolepsy and residual EDS in OSA. It does not induce or inhibit CYP enzymes and does not compromise oral contraceptive efficacy. Heart rate and blood pressure must be monitored routinely.

2. Traditional Stimulants (Second-Line for EDS)

• Methylphenidate & Amphetamine Formulations (Dextroamphetamine, Mixed Amphetamine Salts): Potent monoamine transporter inhibitors and promoters of vesicular dopamine and norepinephrine release.
• While highly effective, they are considered second-line due to frequent adverse effects: tachycardia, hypertension, insomnia, weight loss, anorexia, tolerance development, and potential for abuse or dependence (Schedule II controlled substances).

3. Anticataplectic Agents & Oxybates

• Oxybate Formulations (Sodium Oxybate, Mixed-Salt Oxybate, Once-Nightly Oxybate): Sodium oxybate (the sodium salt of gamma-hydroxybutyrate [GHB]) and mixed-salt oxybate (calcium, magnesium, potassium, and sodium oxybates) are $\text{GABA}_B$ receptor agonists and partial endogenous GHB receptor agonists.
  • Mechanism: Oxybates consolidate slow-wave sleep (Stage N3), dramatically suppress nocturnal sleep fragmentation, and eliminate cataplexy, hallucinations, and sleep paralysis. They also secondarily reduce daytime sleepiness.
  • Dosing Architecture: Standard immediate-release oxybates are taken in two divided nocturnal doses: the first dose at bedtime, and the second dose taken $2.5$ to $4$ hours later. A once-nightly extended-release sodium oxybate (Lumryz, FDA-approved for narcolepsy in 2023) avoids the middle-of-the-night dose.
  • Safety Warnings: Profound central nervous system depression; strictly contraindicated with alcohol, sedative-hypnotics, or other CNS depressants due to fatal respiratory depression risks. High-sodium formulations contain substantial sodium ($~1,640\text{ mg}$ at maximum $9\text{ g}$ dose), necessitating low-sodium oxybate in patients with hypertension, heart failure, or renal impairment.
• REM-Suppressing Antidepressants (Off-Label for Cataplexy): Serotonin and norepinephrine reuptake inhibitors (venlafaxine, duloxetine), SSRIs (fluoxetine), and tricyclic antidepressants (clomipramine).
  • Mechanism: Enhancing noradrenergic and serotonergic transmission potently suppresses REM sleep and abolishes cataplexy.
  • Clinical Caution: Abrupt discontinuation of these agents can precipitate status cataplecticus—a terrifying, continuous, prolonged barrage of cataplectic collapses lasting hours or days.